APTX

Aptinyx Inc.

Last Updated:

Q2 '20

Price

quotes and stock data delayed 15 minutes

Cash

$115.9M

Burn Rate (Qtr)

$12.5M

Company Profile

Through our drug development expertise in brain & CNS disorders, we have developed a unique medicinal chemistry platform to discover novel product candidates. The compounds we have discovered work through modulation of NMDA receptors to avoid caustic effects associated with over-activation or full inhibition.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

NYX-458

Parkinson's Disease Cognitive Impairment

Phase 2 to be initiated

Q1 2021

NYX-783

Post-traumatic stress disorder (PTSD)

Phase 2 To be initiated

H2 2020

NYX-2925

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Phase 2 Readout

H1 2022

NYX-2925

Fibromyalgia

Phase 2 Readout

H1 2022

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon